New Content Screening Platform Advances High-Conte?nt Analysis for Cancer Applicatio?ns
A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research. The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well as the development of three-dimensional models of cancer stem cells and spheroid tumours.
The new Thermo Scientific HCS Studio 2.0, coupled with Thermo Scientific high content analysis platforms, are increasingly being used in cancer biology as they are well suited for large-scale, high-throughput biology, including complex morphological analyses of cells, cell structure, and aggregations of cells in colonies, yet simple enough to be applied to everyday assays such as viability and proliferation.
The Thermo Scientific HCS Studio 2.0 and the ArrayScan XTI High Content Analysis (HCA) platform will be demonstrated during the American Association for Cancer Research (AACR) 105th Annual Meeting (Booth #1107), 5–9 April 2014 at the San Diego Convention Center.
“The challenges posed by complex cancer applications and cell models demand new types of quantitative analysis techniques, and our new software continues to enable researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models,” said Scott Keefer, manager of product marketing, cellular imaging and analysis, Thermo Fisher Scientific. “With our new HCS Studio 2.0 software, coupled with the Thermo Scientific ArrayScan XTI HCA Infinity Configuration enabled for 3D confocal imaging, our customers can address more assay and cell types than ever before while managing the complexities of high-content technology with user-guided, task-oriented software.”
Featuring a validated image processing tool and a powerful yet simple user interface, the HCS Studio 2.0 provides researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models. Additional features include
• Directed Assay or Full Development Environment: Pick from validated assays or a customized design with a full suite of image processing tools
• Simple interactive tools for assay optimization: Best-in-class user tools to improve the performance and accuracy of image analysis on cells
• Seamless Integration: Works with software from Thermo Scientific High-Content Imaging platforms for a scalable quantitative cell analysis platform.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance